Symptomatic cerebral oedema during treatment of diabetic ketoacidosis: Effect of adjuvant octreotide infusion

Diabetology and Metabolic Syndrome

Volumn 2, Issue 1, 2010, Pages

  Seewi, Ora ^a   Vierzig, Anne ^a   Roth, Bernhard ^a   Schönau, Eckhard ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN INSULIN; INFUSION FLUID; INSULIN; OCTREOTIDE; POTASSIUM;

ARTICLE; ARTIFICIAL VENTILATION; BRAIN EDEMA; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIABETIC KETOACIDOSIS; DRUG DOSE REDUCTION; ELECTROENCEPHALOGRAM; HUMAN; HYPERGLYCEMIA; MALE; METABOLIC ACIDOSIS; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 77956548297     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-2-56     Document Type: Article

References (25)

1. New perspectives on the pathogenesis of cerebral edema complicating diabetic ketoacidosis in children. N Glaser, Pediatr Endocrinol Rev 2006 3 379 386 16816806
2. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. HJ Schoch S Fischer HH Marti, Brain 2002 125 2549 2557 10.1093/brain/awf257 12390979
3. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. A Bereket HC Lang TA Wilson, Horm Metab Res 1999 31 172 181 10.1055/s-2007-978716 10226799
4. Treatment with insulin-like growth factor I alters capillary permeability in skin and retina. MA Hussain K Studer EP Messmer ER Froesch, Diabetes 1995 44 1209 1212 10.2337/diabetes.44.10.1209 7556959
5. A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection. PD Lee JM Pivarnik JG Bukar N Muurahainen PS Berry PR Skolnik JL Nerad KA Kudsk L Jackson KJ Ellis N Gesundheit, J Clin Endocrinol Metab 1996 81 2968 2975 10.1210/jc.81.8.2968 8768860
6. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. KM Thrailkill T Quattrin L Baker JE Kuntze PG Compton PM Martha rhIGF-I in IDDM Study Group, Diabetes Care 1999 22 585 592 10.2337/diacare.22.4.585 10189536
7. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor alpha and VEGF. V Poulaki W Quin AM Joussen, et al. J Clin Invest 2002 109 805 815 11901189
8. Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer. C Zhang L Hao L Wang Y Xiao H Ge Z Zhu Y Luo Y Zhang Y Zhang, BMC Cancer 2010 10 184 10.1186/1471-2407-10-184 20459642
9. Insulin and the brain. Z Laron, Arch Physiol Biochem 2009 115 112 116 19485707
10. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. S Ezzat SG Ren GD Braunstein S Melmed, J Clin Endocrinol Metab 1992 75 1459 1463 10.1210/jc.75.6.1459 1281485
11. Pituitary-independent effect of octreotide on IGF-1 generation. A Pokrajac J Frystyk A Flyvbjerg P Trainer, Eur J Endocrinol 2009 160 543 548 10.1530/EJE-08-0822 19141605
12. Somatostatin therapy in the management of resistant diabetic ketoacidosis. Letter. M Bosnak B Dikici O Dogru M Davutoglu K Haspolat, Diabetes Care 2002 25 629 630 10.2337/diacare.25.3.629 11874963
13. Nutrition and somatomedin. XVII. Circulating somatomedin C during treatment of diabetic ketoacidosis. EW Glaser S Goldstein LS Phillips, Diabetes 1987 36 1152 1160 10.2337/diabetes.36.10.1152 3115852
14. Effect of insulin on the IGF system in children with new onset insulin dependent diabetes mellitus. A Bereket CH Lang SL Blethen MC Gelato J Fan RA Frost TA Wilson, J Clin Endocrinol Metab 1995 80 1312 1317 10.1210/jc.80.4.1312 7536205
15. Frequency of sub-clinical cerebral edema in children with diabetic ketoacidosis. NS Glaser SL Wooton-Gorges MH Buonocore JP Marcin A Rewers J Strain J DiCarlo EK Neely P Barnes N Kuppermann, Pediatric Diabetes 2006 2 75 80 10.1111/j.1399-543X.2006.00156.x
16. Diabetic ketoacidosis. J Wolfsdorf ME Craig D Daneman D Dunger J Edge WR Lee A Rosenbloom MA Sperling R Hanas International Society for Pediatric and Adolescent Diabetes, Pediatr Diabetes 2007 8 28 43 10.1111/j.1399-5448.2007. 00224.x 17341289
17. The UK case-control study of cerebral edema complicating diabetic ketoacidosis in children. JA Edge RW Jakes Y Roy M Hawkins D Winter ME Ford-Adams NP Murphy A Bergomi B Widmer DB Dunger, Diabetologia 2006 49 2002 2009 10.1007/s00125-006-0363-8 16847700
18. Continuous low-dose infusion in the treatment of diabetic ketoacidosis in children. MM Martin ALA Martin, J Pediatr 1976 89 560 564 10.1016/S0022- 3476(76)80386-1 822144
19. Quantification of insulin resistance and adaptive blood glucose control in diabetic ketosis and ketoacidosis by the artificial endocrine pancreas with computer algorithm for self-adaptive control. M Shichiri R Kawamori T Murata Y Yamasaki T Morishima H Abe, Horm Metab Res/Supplement Series 1982 12 212 215
20. Dose response to insulin in man: differential effects on glucose and ketone body regulation. DS Schade RP Eaton, J Endocrinol Metab 1977 44 1038 1053 10.1210/jcem-44-6-1038
21. Cerebral crisis in severe diabetic ketoacidosis (DKA) despite adaequate fluid and insulin therapy. Abstract. N Datz WV Schuetz O Kordonouri C Nestoris S Hethey G Engelcke T Danne, Pediatric Diabetes 2009 10 Suppl 11 34
22. Low dose (0.05 units/kg/h) is comparable with standard dose (0.1 units/kg/h) intravenous insulin infusion for the initial treatment of diabetic ketoacidosis in children with type 1 diabetes-an observational study. R Putta D Cooke A Subbarayan E Odeka I Ariyaswansa M Bine I Doughty L Patel R Amin, North West England Paediatric Diabetes Network Pediatric Diabetes 2010 11 12 17 10.1111/j.1399-5448.2009.00536.x 19602154
23. Marked changes in insulin-like growth factor (IGF) system and the phosphorylation of insulin-like growth factor binding protein-1(IGFBP-1) during recovery from diabetic ketoacidosis (DKA). Abstract. ASA Khan KW Siddals EA Gardener K Kaushal KL Tieszen JP New JM Gibson, Diabetologia 2003 46 Suppl 2 242
24. The potential role of octreotide in the treatment of diabetic retinopathy. MB Grant S Caballero, Treat Endocrinol 2005 4 199 203 10.2165/00024677-200504040-00001 16053337
25. Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration-a case report. E Chantelau J Frystyk, Growth Hormone & IGF Research 2005 15 130 135